U.S., Nov. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07247162) titled 'Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome' on Nov. 19.
Brief Summary: Osilodrostat has proven to be a safe and efficacious treatment for patients with CS. Demonstrating normalisation of hypercortisolaemia and in patients with hypertension and/or dysglycaemia clinically relevant and statistically significant reductions in blood pressure and glycaemia. This study aims at providing additional evidence on the safety, efficacy and appropriate dosing of osilodrostat in patients with CS, who have hypertension.
Study Start Date: Aug., 2026
Study Type: INTERVENTIONAL
Condition:
Hype...